Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment.
Morra A., Escala-Garcia M., Beesley J., Keeman R., Canisius S., Ahearn TU., Andrulis IL., Anton-Culver H., Arndt V., Auer PL., Augustinsson A., Beane Freeman LE., Becher H., Beckmann MW., Behrens S., Bojesen SE., Bolla MK., Brenner H., Brüning T., Buys SS., Caan B., Campa D., Canzian F., Castelao JE., Chang-Claude J., Chanock SJ., Cheng T-YD., Clarke CL., NBCS Collaborators None., Colonna SV., Couch FJ., Cox A., Cross SS., Czene K., Daly MB., Dennis J., Dörk T., Dossus L., Dunning AM., Dwek M., Eccles DM., Ekici AB., Eliassen AH., Eriksson M., Evans DG., Fasching PA., Flyger H., Fritschi L., Gago-Dominguez M., García-Sáenz JA., Giles GG., Grip M., Guénel P., Gündert M., Hahnen E., Haiman CA., Håkansson N., Hall P., Hamann U., Hart SN., Hartikainen JM., Hartmann A., He W., Hooning MJ., Hoppe R., Hopper JL., Howell A., Hunter DJ., ABCTB Investigators None., kConFab Investigators None., Jager A., Jakubowska A., Janni W., John EM., Jung AY., Kaaks R., Keupers M., Kitahara CM., Koutros S., Kraft P., Kristensen VN., Kurian AW., Lacey JV., Lambrechts D., Le Marchand L., Lindblom A., Linet M., Luben RN., Lubiński J., Lush M., Mannermaa A., Manoochehri M., Margolin S., Martens JWM., Martinez ME., Mavroudis D., Michailidou K., Milne RL., Mulligan AM., Muranen TA., Nevanlinna H., Newman WG., Nielsen SF., Nordestgaard BG., Olshan AF., Olsson H., Orr N., Park-Simon T-W., Patel AV., Peissel B., Peterlongo P., Plaseska-Karanfilska D., Prajzendanc K., Prentice R., Presneau N., Rack B., Rennert G., Rennert HS., Rhenius V., Romero A., Roylance R., Ruebner M., Saloustros E., Sawyer EJ., Schmutzler RK., Schneeweiss A., Scott C., Shah M., Smichkoska S., Southey MC., Stone J., Surowy H., Swerdlow AJ., Tamimi RM., Tapper WJ., Teras LR., Terry MB., Tollenaar RAEM., Tomlinson I., Troester MA., Truong T., Vachon CM., Wang Q., Hurson AN., Winqvist R., Wolk A., Ziogas A., Brauch H., García-Closas M., Pharoah PDP., Easton DF., Chenevix-Trench G., Schmidt MK.
BackgroundGiven the high heterogeneity among breast tumors, associations between common germline genetic variants and survival that may exist within specific subgroups could go undetected in an unstratified set of breast cancer patients.MethodsWe performed genome-wide association analyses within 15 subgroups of breast cancer patients based on prognostic factors, including hormone receptors, tumor grade, age, and type of systemic treatment. Analyses were based on 91,686 female patients of European ancestry from the Breast Cancer Association Consortium, including 7531 breast cancer-specific deaths over a median follow-up of 8.1 years. Cox regression was used to assess associations of common germline variants with 15-year and 5-year breast cancer-specific survival. We assessed the probability of these associations being true positives via the Bayesian false discovery probability (BFDP ResultsEvidence of associations with breast cancer-specific survival was observed in three patient subgroups, with variant rs5934618 in patients with grade 3 tumors (15-year-hazard ratio (HR) [95% confidence interval (CI)] 1.32 [1.20, 1.45], P = 1.4E-08, BFDP = 0.01, per G allele); variant rs4679741 in patients with ER-positive tumors treated with endocrine therapy (15-year-HR [95% CI] 1.18 [1.11, 1.26], P = 1.6E-07, BFDP = 0.09, per G allele); variants rs1106333 (15-year-HR [95% CI] 1.68 [1.39,2.03], P = 5.6E-08, BFDP = 0.12, per A allele) and rs78754389 (5-year-HR [95% CI] 1.79 [1.46,2.20], P = 1.7E-08, BFDP = 0.07, per A allele), in patients with ER-negative tumors treated with chemotherapy.ConclusionsWe found evidence of four loci associated with breast cancer-specific survival within three patient subgroups. There was limited evidence for the existence of associations in other patient subgroups. However, the power for many subgroups is limited due to the low number of events. Even so, our results suggest that the impact of common germline genetic variants on breast cancer-specific survival might be limited.